Skip to content
10-Q

Quarterly Report

Zenas BioPharma, Inc. ZBIO

0001104659-26-059735

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 63.13M sh
Shares Diluted Q1 2026 · Mar 31, 2026 55.62M sh
Shares Diluted Q1 2026 · Mar 31, 2025 41.8M sh
Capex Q1 2026 · Mar 31, 2026 $2K
Capex Q1 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$75.2M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$37.05M
Short Term Investments Q1 2026 · Mar 31, 2026 $216.98M
Short Term Investments Q1 2026 · Dec 31, 2025 $232.55M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $500.22M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $110.64M
Stockholders Equity Q1 2026 · Mar 31, 2026 $335.83M
Stockholders Equity Q1 2026 · Dec 31, 2025 $242.14M
Stockholders Equity Q1 2026 · Mar 31, 2025 $284.32M
Stockholders Equity Q1 2026 · Dec 31, 2024 $312.46M
Current Liabilities Q1 2026 · Mar 31, 2026 $61.16M
Current Liabilities Q1 2026 · Dec 31, 2025 $62.65M
Total Liabilities Q1 2026 · Mar 31, 2026 $411.85M
Total Liabilities Q1 2026 · Dec 31, 2025 $141.5M
Current Assets Q1 2026 · Mar 31, 2026 $730.16M
Current Assets Q1 2026 · Dec 31, 2025 $351.17M
Total Assets Q1 2026 · Mar 31, 2026 $747.68M
Total Assets Q1 2026 · Dec 31, 2025 $383.64M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.46
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.80
Eps Basic Q1 2026 · Mar 31, 2026 −$1.46
Eps Basic Q1 2026 · Mar 31, 2025 −$0.80
Sga Expense Q1 2026 · Mar 31, 2026 $16.91M
Sga Expense Q1 2026 · Mar 31, 2025 $12.42M
Rd Expense Q1 2026 · Mar 31, 2026 $60.44M
Rd Expense Q1 2026 · Mar 31, 2025 $34.92M
Net Income Q1 2026 · Mar 31, 2026 −$80.99M
Net Income Q1 2026 · Mar 31, 2025 −$33.57M
Operating Income Q1 2026 · Mar 31, 2026 −$77.35M
Operating Income Q1 2026 · Mar 31, 2025 −$37.33M
Revenue Q1 2026 · Mar 31, 2025 $10M